Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 4
1989 3
1990 2
1991 1
1992 1
1993 1
1994 2
1995 2
1997 3
1998 4
1999 1
2000 1
2001 7
2002 2
2003 2
2004 4
2005 2
2006 2
2007 1
2008 1
2009 1
2010 4
2011 1
2012 2
2014 3
2015 3
2016 3
2017 2
2018 2
2019 3
2020 4
2021 5
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Colon Carcinoma"
Page 1
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. Hallin J, et al. Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28. Cancer Discov. 2020. PMID: 31658955 Free PMC article.
MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRAS(G12C)-positive cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been observed in patients with KRAS(G12C)-positive lung and colon adenocarc …
MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRAS(G12C)-positive cell line- and patient-derived xenograft models from …
N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for Immunotherapy.
Krug J, Rodrian G, Petter K, Yang H, Khoziainova S, Guo W, Bénard A, Merkel S, Gellert S, Maschauer S, Spermann M, Waldner M, Bailey P, Pilarsky C, Liebl A, Tripal P, Christoph J, Naschberger E, Croner R, Schellerer VS, Becker C, Hartmann A, Tüting T, Prante O, Grützmann R, Grivennikov SI, Stürzl M, Britzen-Laurent N. Krug J, et al. Gastroenterology. 2023 Mar;164(3):392-406.e5. doi: 10.1053/j.gastro.2022.11.018. Epub 2022 Nov 17. Gastroenterology. 2023. PMID: 36402190 Free PMC article.
BACKGROUND & AIMS: Advanced colorectal carcinoma (CRC) is characterized by a high frequency of primary immune evasion and refractoriness to immunotherapy. ...RESULTS: The conditional knockout of the IFN-gamma receptor in intestinal epithelial cells enhanced spon …
BACKGROUND & AIMS: Advanced colorectal carcinoma (CRC) is characterized by a high frequency of primary immune evasion and refr …
TroVax in colorectal cancer.
Rowe J, Cen P. Rowe J, et al. Hum Vaccin Immunother. 2014;10(11):3196-200. doi: 10.4161/21645515.2014.973323. Hum Vaccin Immunother. 2014. PMID: 25483641 Free PMC article. Review.
Currently, the backbone of therapy for metastatic disease is cytotoxic chemotherapy, along with the recent addition of targeted therapy based on molecular markers with KRAS testing. Despite the improvement in survival for metastatic colon cancer, newer agents are still nee …
Currently, the backbone of therapy for metastatic disease is cytotoxic chemotherapy, along with the recent addition of targeted therapy base …
Clinicopathological and Molecular Characteristics of Colorectal Signet Ring Cell Carcinoma: A Review.
An Y, Zhou J, Lin G, Wu H, Cong L, Li Y, Qiu X, Shi W. An Y, et al. Pathol Oncol Res. 2021 Jul 26;27:1609859. doi: 10.3389/pore.2021.1609859. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34381313 Free PMC article. Review.
Colorectal signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC) with unique characteristics. ...Understanding the special molecular mechanisms related to the aggressive biology of SRCC is of great importance, which may provide a theoretical basis …
Colorectal signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC) with unique characteristics. ...Understandi …
KRAS mutation testing in colorectal cancer.
Plesec TP, Hunt JL. Plesec TP, et al. Adv Anat Pathol. 2009 Jul;16(4):196-203. doi: 10.1097/PAP.0b013e3181a9d4ed. Adv Anat Pathol. 2009. PMID: 19546608 Review.
Approximately 20% of patients present with metastatic disease, and an additional 30% to 40% develop metastasis during the course of their disease. Patients with metastatic colon cancer have a 5-year survival rate of only 11%. Although surgery is the mainstay of treatment f …
Approximately 20% of patients present with metastatic disease, and an additional 30% to 40% develop metastasis during the course of their di …
New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
Gheysen L, Soumoy L, Trelcat A, Verset L, Journe F, Saussez S. Gheysen L, et al. Cells. 2021 May 5;10(5):1112. doi: 10.3390/cells10051112. Cells. 2021. PMID: 34063063 Free PMC article.
Although the overall survival rate of papillary or follicular thyroid cancers is good, anaplastic carcinomas and radio iodine refractory cancers remain a significant therapeutic challenge. ...OTX008 is a calixarene derivative designed to bind the Gal-1 amphipathic b …
Although the overall survival rate of papillary or follicular thyroid cancers is good, anaplastic carcinomas and radio iodine refr …
High prevalence of ulcerative appendicitis in patients with ulcerative colitis.
Heuthorst L, Mookhoek A, Wildenberg ME, D'Haens GR, Bemelman WA, Buskens CJ. Heuthorst L, et al. United European Gastroenterol J. 2021 Dec;9(10):1148-1156. doi: 10.1002/ueg2.12171. Epub 2021 Nov 9. United European Gastroenterol J. 2021. PMID: 34750986 Free PMC article.
Histological features of UC appendices were compared to those of patients with acute appendicitis and colon carcinoma. The Robarts Histopathology Index (RHI) was used to assess appendiceal inflammation. ...Endoscopic response (Mayo 0-1) following appendectomy, asses …
Histological features of UC appendices were compared to those of patients with acute appendicitis and colon carcinoma. The Rob …
Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.
Wichmann CW, Burvenich IJG, Guo N, Rigopoulos A, McDonald A, Cao D, O'Keefe GJ, Gong SJ, Gan HK, Scott FE, Pore N, Coats S, Scott AM. Wichmann CW, et al. Nucl Med Biol. 2023 Jul-Aug;122-123:108366. doi: 10.1016/j.nucmedbio.2023.108366. Epub 2023 Jul 14. Nucl Med Biol. 2023. PMID: 37473513
Although promising efficacy was observed in the clinic, pharmacokinetic (PK) analyses observed low exposure of MEDI7247 in phase I hematological patients. ...In vivo biodistribution and whole body PET/MRI imaging studies of [(89)Zr]Zr-Df-MEDI7519 and [(89)Zr]Zr-Df-M …
Although promising efficacy was observed in the clinic, pharmacokinetic (PK) analyses observed low exposure of MEDI7247 in pha …
Clinical aspects of ulcerative colitis in mainland China.
Zheng JJ. Zheng JJ. Chin J Dig Dis. 2006;7(2):71-5. doi: 10.1111/j.1443-9573.2006.00251.x. Chin J Dig Dis. 2006. PMID: 16643333 Review.
Compared to patients in Western countries, more mild to moderate and left-sided colitis cases were observed in a nation-wide study in China. Complications included anal fistula, anal abscess, anal fissure, severe bleeding, intestinal perforation, intestinal obstruction and …
Compared to patients in Western countries, more mild to moderate and left-sided colitis cases were observed in a nation-wide study in …
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM. Senderowicz AM. Leukemia. 2001 Jan;15(1):1-9. doi: 10.1038/sj.leu.2401994. Leukemia. 2001. PMID: 11243375 Review.
Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with non-Hodgkin's lymphoma, renal, prostate, colon and gastric carcinomas. Main side-effects were secretory diarrhea and a pro-inflammatory syndrome associated with hypotens …
Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with non-Hodgkin's lymphoma, renal, prostate, …
79 results